

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 November 2024 (21.11.2024)



(10) International Publication Number
WO 2024/235265 A1

(51) International Patent Classification:

A61K 35/28 (2015.01) A61P 25/00 (2006.01)
A61K 9/00 (2006.01) A61K 38/22 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2024/093397

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

15 May 2024 (15.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023901470 15 May 2023 (15.05.2023) AU

(71) Applicant: **STEMINENT BIOTHERAPEUTICS INC.**

[CN/CN]; No. 16, WenHu Street, NeiHu Dist., Taipei, Taiwan (CN).

(72) Inventors: **LO, Wei-Chi**; No. 16, WenHu Street, NeiHu

Dist., Taipei, Taiwan (CN). **ONG, Wei-Kee**; No. 16, WenHu Street, NeiHu Dist., Taipei, Taiwan (CN). **LAI, Hsiu-Yu**; No. 16, WenHu Street, NeiHu Dist., Taipei, Taiwan (CN).

(74) Agent: **LIU, SHEN & ASSOCIATES**; 10th Floor, Building 1, 10 Caihefang Road, Haidian District, Beijing 100080 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS FOR TREATING POLYQ DISEASE AND NOVEL ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS

(57) Abstract: Provided is the use of adipose tissue derived stem cells that express Activin A or the combination of Activin A and modified adipose tissue derived stem cells, for treating polyQ diseases, such as spinocerebellar ataxia 3 (SCA 3), by reducing a misfolded and aggregated polyQ protein, such as ataxin-3 protein. Also provided is a composition for reducing misfolded and aggregated polyQ proteins, wherein the composition comprises a population of modified adipose tissue derived stem cells and Activin A.



WO 2024/235265 A1